gut microbiota

Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert

This partnership aims to leverage Microba's advanced technology platform for measuring the human gut microbiome to discover novel biomarkers for pancreatic cancer detection. 

Gut microbes sway how people with lymphoma respond to immunotherapy

The findings of a recent study identified microbiota signatures that may allow clinicians to predict the outcomes of CAR-T immunotherapy.

Gut bacteria Parabacteroides Distasonis: a new hope for the treatment of inflammatory arthritis

The findings of a recent study reveal that P. distasonis and its metabolites could be promising candidates for treating RA.

Gut microbiome affects tumor regression of oncolytic adenovirus-treated melanoma

Microbiomepost discussed with Lorella Tripodi, University Federico II of Naples, about the research she is working with her colleagues.

A mother’s diet can change the infant microbiota, prevent respiratory infection

Diet-induced changes in the gut microbiota confer protection against respiratory infections by regulating the development of key components of the immune system.

How the sex hormone-gut microbiome axis influences tumor immunotherapy

Numerous evidences demonstrate the involvement of the sex hormone-gut microbiome axis in regulating the antitumor efficacy of ICIs.

The most promising future application of microbiome science discussed at MicrobiotaMI congress

Microbiomepost discussed with Nicasio Mancini about the role of gut microbiome in immune response and in the antibiotic resistance.

How a common bacterium colonizes the gut

The findings of a recent study suggest that other gut microbes use liquid-liquid phase separation to colonize the gut, opening the way for new microbiota-based clinical applications.

Some gut microbes are associated with depression in premenopausal women

The findings of a recent study suggest that estradiol-degrading bacteria could be therapeutic targets for treating depression in some women.

MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology, which provides greater…

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top